Inari Medical’s (NARI) “Neutral” Rating Reiterated at Robert W. Baird

Robert W. Baird reaffirmed their neutral rating on shares of Inari Medical (NASDAQ:NARI) in a research report released on Tuesday,Benzinga reports. They currently have a $80.00 price target on the stock, down from their prior price target of $81.00.

A number of other equities analysts have also weighed in on NARI. Canaccord Genuity Group reissued a “hold” rating and issued a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday. Oppenheimer began coverage on shares of Inari Medical in a research report on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price objective on the stock. Stifel Nicolaus initiated coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price for the company. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Finally, Truist Financial lifted their price objective on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Inari Medical presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Trading Down 0.2 %

Inari Medical stock opened at $79.30 on Tuesday. Inari Medical has a 12 month low of $36.73 and a 12 month high of $79.69. The stock has a fifty day simple moving average of $53.49 and a two-hundred day simple moving average of $49.14. The firm has a market cap of $4.64 billion, a price-to-earnings ratio of -58.74 and a beta of 0.97.

Insider Buying and Selling at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. This represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the completion of the sale, the director now directly owns 238,987 shares in the company, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 406,000 shares of company stock valued at $22,621,870 in the last three months. 10.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Inari Medical

A number of large investors have recently made changes to their positions in NARI. Commonwealth Equity Services LLC bought a new position in Inari Medical during the second quarter valued at $421,000. Arizona State Retirement System grew its holdings in Inari Medical by 2.5% during the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock valued at $703,000 after purchasing an additional 358 shares during the last quarter. Quest Partners LLC raised its position in Inari Medical by 31,257.1% in the 2nd quarter. Quest Partners LLC now owns 2,195 shares of the company’s stock worth $106,000 after purchasing an additional 2,188 shares during the period. American Century Companies Inc. lifted its stake in Inari Medical by 26.8% in the second quarter. American Century Companies Inc. now owns 980,917 shares of the company’s stock worth $47,231,000 after purchasing an additional 207,485 shares during the last quarter. Finally, Sofinnova Investments Inc. boosted its position in shares of Inari Medical by 1,425.4% during the second quarter. Sofinnova Investments Inc. now owns 155,838 shares of the company’s stock valued at $7,504,000 after buying an additional 145,622 shares during the period. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.